Atrium Therapeutics, Inc. RNA
Atrium Therapeutics, Inc. (Nasdaq: RNA) is a cardio-renal-metabolic drug developer. Its lead program, ATR 1072, is in Pre-clinical for PRKAG2 syndrome. Its next catalyst on record is ATR 1072: Atrium expects initial proof of concept data from the Phase 1/2 Corventis trial in the second half of 2027. (H2 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ATR 1072 — Atrium expects initial proof of concept data from the Phase 1/2 Corventis trial in the second half of 2027. (H2 2027). 6 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ATR 1072 | PRKAG2 syndrome | RNA (siRNA/ASO/mRNA) | Pre-clinical |
| ATR 1086 | PLN cardiomyopathy | RNA (siRNA/ASO/mRNA) | Pre-clinical |
| Undisclosed rare cardiomyopathy programs (2) | — | RNA (siRNA/ASO/mRNA) | Pre-clinical |
Recent results and decisions
- Nov 2, 2026positive Nonclinical data show ATR 1072 reversed cardiac glycogen accumulation and improved key features of PRKAG2 syndrome in a mouse model.
mATR 1072 treatment led to reversal of cardiac glycogen accumulation as well as improvement in other key features of the disease, including hypertrophy and ECG parameters.
Filing - Nov 2, 2026positive Nonclinical data showed mATR 1072 reversed cardiac glycogen accumulation and improved key features of PRKAG2 syndrome in a mouse model.
By targeting disease causing variant PRKAG2 mRNA in the heart, mATR 1072 treatment led to reversal of cardiac glycogen accumulation as well as improvement in other key features of the disease, including hypertrophy and ECG parameters.
Filing - Oct 27, 2026started Atrium Therapeutics doses first patient in Phase 1/2 Corventis trial of ATR 1072 for PRKAG2 syndrome.
Dosing the first patient in the Corventis clinical trial is a milestone for Atrium and, more importantly, for the PRKAG2 community.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical cardio-renal-metabolic companies
- Editas Medicine, Inc. EDIT
- Cellectis S.A. CLLS
- NewcelX Ltd. NCEL
- Fractyl Health, Inc. GUTS
- Alaunos Therapeutics, Inc. TCRT
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.